K
260660
vs
K
KOSPI 200
Over the past 12 months, Korea Arlico Pharm Co Ltd has underperformed KOSPI 200, delivering a return of +5% compared to KOSPI 200's +150% growth.
Stocks Performance
260660 vs KOSPI 200
Performance Gap
260660 vs KOSPI 200
Performance By Year
260660 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Korea Arlico Pharm Co Ltd
Glance View
Korea Arlico Pharm Co., Ltd. engages in the provision of development and manufacture of pharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 228 full-time employees. The company went IPO on 2018-02-12. The firm manufactures and sells medicines such as hyperlipidemia, cerebrovascular disease, digestive medicine, allergies, respiratory medicine and others. In addition, the Company is also engaged in the manufacture of non-pharmaceutical products such as sun cream, hand cream and medical devices. The firm sells its products in domestic and overseas markets.
